Triple negative breast cancer (TNBC) represents a molecularly and clinically diverse disease with cytotoxic chemotherapy the only systemic treatment modality, and no targeted agents approved in adjuvant, neoadjuvant, or metastatic settings. We demonstrate that a significant population of aggressive high-grade TNBCs overexpress the cell surface tumor-associated antigen Folate Receptor alpha (FRα) and molecules involved in folate metabolism. Importantly, FRα is expressed in post-neoadjuvant chemotherapy residual disease, associated with worse clinical outcomes, and participates in cancer cell signaling and growth. We show that FRα may present a promising target for therapeutic strategies such as antibody-drug conjugates, or antibody immunotherapy that primes an Fc-mediated anti-tumor immune response in vitro and in vivo in the human patient breast cancer and the patient immune context. Engineering antibodies targeting FRα-expressing breast cancers may provide new strategies to treat patients with poor prognosis who do not adequately benefit from currently-available targeted, and immunooncology therapies.
Translational Relevance
Triple negative breast cancer (TNBC) represents a molecularly and clinically diverse disease with cytotoxic chemotherapy the only systemic treatment modality, and no targeted agents approved in adjuvant, neoadjuvant, or metastatic settings. We demonstrate that a significant population of aggressive high-grade TNBCs overexpress the cell surface tumor-associated antigen Folate Receptor alpha (FRα) and molecules involved in folate metabolism. Importantly, FRα is expressed in post-neoadjuvant chemotherapy residual disease, associated with worse clinical outcomes, and participates in cancer cell signaling and growth. We show that FRα may present a promising target for therapeutic strategies such as antibody-drug conjugates, or antibody immunotherapy that primes an Fc-mediated anti-tumor immune response in vitro and in vivo in the human patient breast cancer and the patient immune context. Engineering antibodies targeting
Introduction
Triple negative breast cancer (TNBC), defined by lack of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression, represents an urgent unmet clinical need for treatment options. This is largely due to its aggressive nature and lack of suitable therapeutic targets. TNBC is a heterogeneous disease at the cellular and molecular levels, with its diverse phenotypes correlating with different drug resistance and clinical outcomes (1) . Gene expression profiling and expression signatures have identified five molecularly-distinct types of breast cancers, including ER-positive luminal (luminal A and B), HER2-positive, normal-like and basal-like (BL) subtypes. The majority of BL carcinomas have a high mitotic rate, and are usually triple-negative (2) . Different TNBC subgroups also correlate with risk factors, incidence, prognosis and treatment response (3) . The Lehman-Pietenpol expression classification crystallizes six further TNBC subtypes with implications for prediction of prognosis and chemotherapy sensitivity (4) . Although TNBCs are largely defined by a clinical diagnosis of exclusion based on pathological parameters, together these studies point to the potential for identification of disease-associated markers which may serve to define patient subgroups and lead to personalized targeted therapy.
At present, no targeted treatments are standard of care for TNBC. Antibodies recognizing growth factor receptors such as cetuximab or bevacizumab (5, 6) , and small molecule drugs such as dovitinib and cabozantinib (7, 8) , have been explored in clinical trials, alone or in combination with chemotherapy. These have shown relatively limited response rates in unselected patient populations (9) , most likely due to activation of alternative compensatory pathways and inter-/intra-tumoral heterogeneity in expression and mutational status, which may be responsible for intrinsic and acquired resistance-driving mechanisms (10) . Thus, disease management mostly relies on a combination of surgery, radiotherapy and multiple chemotherapeutic agents, often associated with high risk of local and systemic relapse (11) .
Folate Receptor alpha (FRα) and its ligand folate are central mediators of cell growth regulation for the one-carbon metabolic reaction and DNA biosynthesis, repair and methylation (12) . Insights into FRα distribution (high expression in tumors and restricted expression in normal tissues), alongside emerging roles in cancer growth and metastasis have led to renewed interest in this as a therapy target (13, 14) . Preclinical Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR- farletuzumab (15) and MOv18-IgG1 (16), antibody-drug conjugate (ADC) Mirvetuximab Soravtansine (17) , and small molecule drug vintafolide (18) . Encouraging results have recently been reported for the thymidylate synthase inhibitor ONX-0801 in ovarian carcinoma (19) . The FRα-targeted hapten immunotherapeutic regimen, Folate Immune, was designed to render tumors more immunogenic; however, a phase II trial in renal carcinoma was terminated due to low patient accrual (NCT00485563). Another phase I trial of a FRα-specific chimeric antigen receptor (CAR)-T cell therapy in ovarian cancer patients showed no reduction in tumor burden (20) . Recently, Song et al. showed that new generation FRα-specific CAR-T cells significantly inhibited high FRα-expressing TNBC xenograft growth (21) . However, monoclonal antibody therapeutics agents targeting FRα are yet untested in TNBC.
In this study, we examined FRα as a target for monoclonal antibody therapy approaches.
We ascertained the clinical and biological significance of FRα in TNBC and the largely overlapping basal-like subtype, associations of FRα expression with clinical parameters and outcomes by genomic and immunohistochemical analyses. We employed RNA interference and cell-based functional assays to interrogate how FRα may contribute to breast cancer cell biology. We studied FRα and its downstream folate pathway as therapeutic targets by assessing the potential anti-tumor functions of an antibody recognizing FRα (MOv18-IgG1); as an ADC to inhibit cellular viability in vitro and tumor growth in vivo; and as immunotherapy to activate human immune cells against TNBC in vitro, in orthotopic and patient-derived tumor xenografts (PDTX) in vivo, more likely able to recapitulate the complexity and heterogeneity of human disease (22) . Our findings define FRα as a promising target for antibody therapies for basal-like breast carcinomas including TNBCs. 
Materials and Methods

Cell lines
Cell lines were obtained from King's College London (KCL) Breast Cancer Now Unit, except HDQ-P1, purchased from Leibniz Institute DSMZ. Cell lines were authenticated by short tandem repeat profiling. Cells used once tested negative for mycoplasma and used up to 30 passages.
Gene expression data of human breast cancers
The KCL Guy's Hospital, METABRIC and TCGA Breast cohorts (N=2012) interrogated were previously reported (23, 24, 25) . Statistical analyses and respective data plots were generated in R version 3.2.2. 
Tissue microarray (TMA) and immunohistochemistry (IHC)
siRNA-and lentiviral-mediated RNA interference
FRα-targeting siRNA sequences and scrambled duplex were purchased from OriGene.
Transient transfection was performed using Lipofectamine2000 (Thermo Fisher Scientific). were transduced using 1:30 viral dilution of isolated viral supernatant. Successfully transduced clones were selected after 48 hr with 3 μg/ml of puromycin for 5 days, and 1 μg/ml of doxycycline was used to induce FRα knockdown.
In vitro viability and clonogenic assay
Cell viabilities were detected by methyl tetrazolium assay (Promega). Optical absorbance was read on FLUOstar Omega spectrophotometer (BMG Labtech) to determine viable cell counts after 96 hr. For clonogenic assays, cells were fixed by methanol, stained with crystal violet solution (Sigma Aldrich). Colonies were measured as a function of mean pixel density per well. Image analysis was performed using ImageJ.
Western blot and Human Phospho-Kinase Antibody Array
Immunoblottings were analyzed with anti-phospho-ERK1/2 (Thr202/Tyr04) (Biolegend) and anti-ERK1/2 (Cell Signalling). Proteome Profiler Human Phospho-Kinase Antibody Array (R&D Systems) were incubated with 470 μg lysate overnight at 4°C. The following day, chemiluminescent detection was done according to manufacturer's protocols.
Densitometry analysis was performed using ImageJ.
Antibody-drug conjugate production
MOv18-IgG1 was linked to streptavidin overnight using Lightning-Link Streptavidin Conjugation Kit (Expedeon) according to manufacturer's protocol. A-419259 (Cayman Chemical) was biotinylated using EZ-Link-Sulfo-NHS-Biotin (Thermo Fisher Scientific): 10 mM solution in PBS added to 10 mM EZ-Link-Sulfo-NHS-Biotin in ultrapure water (molar ratio 8:1), incubated at room temperature for 30 min, 133 μl of 1.1 mM solution of biotinylated A-419259 was added per 1 mg of streptavidin-conjugated MOv18-IgG1, followed by 30 min incubation. The ADC was purified by centrifugation using 3K Amicon ultra centrifugal filters six times, then resuspended in PBS for functional experiments.
Fluorescence-based tumor cell killing assays
For live-dead cell cytotoxicity imaging, cancer cells were stained with 5 μM CFSE (Life Technologies). The following day, human peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Paque PLUS (GE Healthcare) and stained with CellTracker Blue dye (Thermo Fisher Scientific). PBMCs were incubated with cancer cells and MOv18-IgG1
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Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR- or isotype antibody. Ethidium homodimer-1 (4 μM) (Thermo Fisher Scientific) served to label dead cells. Samples were imaged using Eclipse Ti-2 inverted microscope equipped with Nikon DS-Qi2 sCMOS camera and running NIS Elements. Antibody-dependent cellmediated killing of tumor cells was quantified as previously described (26) . Data were acquired using FACSCanto flow cytometer (BD Biosciences).
In vivo procedures
Animals were handled in accordance with Institutional Committees on Animal Welfare (The Home Office Animals Scientific Procedures Act, 1986). Antibody-drug conjugate: Six-weekold female CD-1 nude mice were used for orthotopic injection of 1 × 10 6 CAL51 cells (50 μl PBS mixed in 50 μl Matrigel) (day 1). On day 5, mice received single intravenous injection of 7.5 mg/kg ADC or MOv18-IgG1, or 5 mg/kg A-419259. Tumors were measured with calipers and volumes calculated (π × length × width 2 / 6). Experiments were terminated after 28 days when tumor sizes were ≤ 525 mm 3 . Antibody immunotherapy: Female NSG mice were orthotopically injected with 1 × 10 6 CAL51 cells or 0.25 × 10 6 WHIM02 PDTX single cell digests in 50 μl PBS:50 μl Matrigel (day 1). For CAL51, on days 5 and 19, each mouse received 12 × 10 6 human peripheral blood lymphocytes (PBLs) (following red blood cell lysis of human blood) intravenously and 5 or 10 mg/kg MOv18-IgG1. Subsequent antibody was given once per week. For WHIM02, on days 5 and 18, 12 × 10 6 human PBLs and 10 mg/kg antibody per mouse were given intravenously. Antibody doses were given three times in week one and subsequently twice per week. Experiments were terminated after 33 days for CAL51 and 20 days for WHIM02, and tumor sizes were ≤ 525 mm 3 .
Tumor engraftment of human immune cells was confirmed by IHC staining and flow cytometry (antibody panel: rat anti-mouse CD45-V500; mouse anti-human CD45-PE-Cy7, CD20-APC, CD3-APC-Cy7, CD68-PE (all BD Biosciences), CD14-PE (eBioscience), CD56-PercP Cy5.5 (Cambridge Bioscience).
Statistical analyses
GraphPad Prism was used for statistical analyses. Data were presented as mean ± standard error of the mean (SEM). Differences with P-values < 0.05 were considered statistically significant and all tests were two-sided.
Please see Supplementary Experimental
Procedures for more detailed methods. 
Results
Gene expression pattern of FRα reveal associations with TNBC and basal-like breast cancer
We investigated whether FRα (FOLR1) is expressed in TNBC and its majority basal-like subtype by interrogating three transcriptomic datasets: METABRIC (N = 1197) (25), The Cancer Genome Atlas (TCGA) (N = 638) (24) and the KCL TNBC-enriched cohort (N = 177) (23) . When tumors were stratified by IHC-defined status, FOLR1 levels were significantly higher in TNBC compared with non-TNBC ( Fig. 1A) . FOLR1 expression was also higher in the basal-like molecular subtype defined by PAM50 classification (Fig 1B) .
The small changes of DNA copy number in the genome suggest that copy number had an insignificant impact on FOLR1 expression ( Supplementary Fig. 1A ). FOLR1 was expressed in all TNBC subtypes as classified by the Lehman-Pietenpol method ( Supplementary Fig. 1B ).
Although plasma folate levels have not been clearly associated with breast cancer risk (27) , low folate status can lead to hypomethylation, subsequent dysregulation of onecarbon metabolism and DNA instability. This may in turn influence the levels of folate receptors or folate carriers (28) . However, the association between breast cancer and folate status in the tumor microenvironment remains undetermined. We investigated three molecules involved in folate metabolism that may be of therapeutic interest in cancer. We found that mRNA levels of methylenetetrahydrofolate reductase (MTHFR), a key enzyme in the folate metabolic pathway, are significantly decreased in METABRIC and TCGA cohorts, although not in the KCL dataset (possibly due to enriched TNBC and low non-TNBC patient tumor groups). Furthermore, Thymidylate Synthase (TYMS), a folatedependent enzyme involved in the biosynthesis of thymidine for DNA synthesis and repair (29) , was upregulated in all datasets. There was no significant correlation between FOLR1 and MTHFR or TYMS expression, suggesting that FRα and folate carriers may be independently-regulated in tumors. Notably, expression of folate hydrolase 1 (FOLH1, also known as prostate specific membrane antigen (PSMA)), a transmembrane folate hydrolase overexpressed in prostate and breast cancers (30) , was higher in TNBC/basallike subtypes. We found a weak correlation between FOLH1 with FOLR1 expression (Pearson's r = 0.31, p < 0.0005) (Fig. 1C) , perhaps suggesting collaborative roles in the tumor microenvironment. Furthermore, the ten-year overall survival (OS) of patients with high FRα tumor expression was significantly lower than those with medium/low expression (Hazard Ratio (HR) = 1.38, P = 0.0097) in all breast cancers (N = 1402) ( Fig. 1Di ). Survival analysis of the TNBC patient subset revealed that despite small cohort size (N = 47), high FRα expression correlated with decreased OS (HR = 3.35, P = 0.043) ( Fig. 1Dii ).
Thus, elevated FRα gene expression and dysregulated expression of molecules involved in folate metabolism were detected in basal-like breast carcinomas including TNBCs, and FRα expression was associated with worse patient outcomes.
FRα membrane expression by immunohistochemical evaluations
We next examined FRα expression on a cross-sectional study of breast carcinoma TMA specimens (N = 323, of which 76 were TNBCs) ( Fig. 2A) . In contrast to a restricted distribution pattern in normal tissues (31) , high frequency (>70%) FRα protein expression correlated with high grade disease (Grade I: 0.0%; II: 7.7%; III: 24.7%). Three quarters of the FRα-positive grade III samples displayed a medium (41-70%) or a high (71-100%) percentage of cancer cells with membrane FRα immunostaining. Expression was less frequently-associated with ER-positive (7.5%), HER2 (15.6%) or luminal (6.5%) tumors, relative to ER-negative tumors (30.0%) and TNBC (36.8%) (by IHC classification). FRα expression in TNBCs vary among studies, from 20% (32) to 67% or 80% positivity (33, 34) . According to PAM50 molecular classification, we observed FRα expression in 10.7% of HER2-positive and 7.1% of luminal A cancers, while FRα expression was more common in basal-like subtypes (33.3%) ( Supplementary Table 1 ) in concordance with a recent report (32) . Furthermore, cell membrane FRα immunostaining, significantly correlated with mRNA expression in the same patient samples (P < 0.0005) ( Fig. 2B ). We also found that 13% of samples negative for membrane FRα demonstrated cytoplasmic, non-membrane, FRα staining; these tissues may not be amenable to anti-FRα antibody treatment.
Due to lack of effective targetable oncogenic drivers, treatment for TNBC commonly involves cytotoxic chemotherapy, often given prior to surgery. A subpopulation of chemotherapy-resistant residual tumor cells remaining in breast tissue may be responsible for high metastatic recurrence rates and poor long-term clinical outcomes (35, 36) . In a TMA containing eighteen TNBC samples from patients with residual disease post-NACT, we found FRα expression in 61.1% of residual tumors (Fig. 2C) , and >75% of positive In summary, more TNBC specimens have FRα-positive immunostaining than other breast cancer subtypes. This is particularly marked in post-NACT residual disease, suggesting that FRα could be therapeutically targeted.
FRα expression contributes to breast cancer growth
To gain insights into FRα functions, we evaluated FRα expression in twenty-two breast cancer cell lines by flow cytometry using the monoclonal antibody MOv18-IgG1 ( Traditionally FRα has been viewed as an intracellular transporter of soluble folate.
However, recent findings indicate that FRα may form macromolecular complexes in which it may contribute to upregulation of oncogenic STAT3/JAK pathways (37) and Lyn signaling (38) . We therefore hypothesized that FRα expression may confer a proliferative advantage to high-expressing tumors. Employing RNA interference, we found that FRα expression (mean fluorescence intensity, MFI) in cells treated with FRα-targeting siRNA (siFRα) was significantly lower than in those treated with non-targeting siRNA (siNT) ( Supplementary   Fig. 2D ). Reduction in FRα was accompanied by reduced cell viability compared with scrambled siRNA-treated cells ( Fig. 3C, Supplementary Fig. 2E ). FRα knockdown also resulted in reduction of colony formation ( Fig. 3C, Supplementary Fig. 2F Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Furthermore, we studied the anti-tumor effects of raltitrexed, a highly-selective inhibitor of thymidylate synthase, the key enzyme in folate metabolism (Fig. 1 ). CAL51 shNT cells (with high FRα expression levels) were more sensitive to raltitrexed compared to FRαknockdown cells in both normal or folate-free conditions (Fig. 3E ).
Together, these data indicate that FRα plays key roles in cell growth and TNBC may be sensitive to therapeutic treatment targeting the folate cycle.
FRα-dependent signaling functions in breast cancer cells
We sought to interrogate the molecular signaling processes regulated by FRα and explore the development of targeted therapeutic options. Signaling pathways were assessed using a human phosphokinase array studied in shNT-and shFRα-transduced CAL51 (Fig. 4A ). Growth inhibition by the broad spectrum Src-family kinase inhibitor A-419259 was observed in cell lines with high FRα expression, but not with MDA-MB-231 which express near background levels of FRα (Fig. 4B) . Growth inhibition was also demonstrated in CAL51 using a second Src-family kinase inhibitor AZM475271 ( Supplementary Fig. 3C ).
The A-419259 inhibitor (50nM) also significantly reduced colony formation to 31.2 ± 4% (P < 0.0005) and ERK activation to 54.6 ± 9.2% (P < 0.005) (Fig. 4B) .
These data suggest that FRα is upstream of multiple Src-family kinases and ERK (Fig.   4C ), known to be involved in breast cancer biology, and identify FRα as cell surface molecule associated with signaling and growth, with potential to be targeted in therapeutic strategies for TNBC. Supplementary Fig. 3D ). This suggested that any direct anti-tumor effects of these agents may be limited to folate-depleted environments, perhaps akin to conditions found in tumors.
MOv18-IgG1 did not engender significant direct inhibition of FRα-dependent signaling under physiological conditions. We therefore developed a FRα-targeting antibody-coupled inhibitor ADC strategy by conjugating the Src-family kinase inhibitor A-419259 to MOv18-IgG1, using the antibody as a vehicle to specifically deliver the inhibitor to cancer cells.
Cell viability assessments resulted in significantly-lower IC 50 Our findings demonstrate the therapeutic potential of ADC targeting FRα and downstream pathways against breast cancer.
MOv18-IgG1 induces tumor cell killing by human immune cells
We next evaluated the potential of MOv18-IgG1 to activate immune effector cells against cancer cells. In a live-dead cell cytotoxicity imaging assay, human PBMCs pre-labeled with CellTracker Blue dye served as immune effector cells, and CFSE-labelled CAL51 were used as targets. We observed higher rates of dead cells (red fluorescent cells, depicting ethidium homodimer-1 incorporation into dead cells) with MOv18-IgG1 compared with control antibody treatments (Fig. 5A) . We quantified tumor cell killing (Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Phagocytosis (ADCP)) by MOv18-IgG1 using a flow cytometry-based assay (26) . With U937 human monocytes as effector cells ( Supplementary Fig. 4A ), MOv18-IgG1 mediated killing of FRα-expressing, but not of low FRα-expressing cancer cells by a combination of ADCC and ADCP functions ( Fig. 5B ; Supplementary Fig. 4C ). MOv18-IgG1 induced predominantly ADCP effects (ADCC vs ADCP ratios: CAL51 = 1.6:1, T47D = 0.4:1, HDQ-P1 = 0.5:1). These effector functions are consistent with previously-reported tumor cell killing engendered by human monocytes and tumor antigen-specific IgG1 antibodies (26, 39) .
Breast cancer patients' immune responses may be suppressed, and patient immune profiles may be altered by adjuvant radiotherapy or chemotherapy (40) , hence potentially less capable of restricting tumor growth. MOv18-IgG1 could stimulate immune effector cells (PBMC) from healthy volunteers and patients with TNBC (patient characteristics: Supplementary Fig. 4D ) to kill CAL51 in an antigen-specific manner (ADCC vs ADCP ratio: healthy volunteers 0.8:1; TNBC patients 0.7:1) ( Fig. 5C, Supplementary Fig. 4E and 4F) .
These data demonstrate the ability of an anti-FRα antibody to activate patient immune effector cells to induce breast cancer cell death in vitro.
Anti-FRα antibody treatment restricts the growth of two orthotopic TNBC human xenograft tumors in vivo
We examined the potential Fc-mediated anti-tumor effects of MOv18-IgG1 in vivo. We Immunohistochemical evaluations of established xenografts confirmed in situ FRα expression in mammary orthotopically-formed CAL51 tumors (Fig. 6A ). Tumors from mice given PBL showed human immune cell (CD45 + ) infiltration in immunohistochemical evaluations (Fig. 6B) , confirmed by flow cytometric assessments of human CD45 + cells extracted from xenografts. MOv18-IgG1-treated animals at either 5 or 10 mg/kg dosages showed significantly reduced tumor growth and resected tumor weights ( Fig. 6C) compared with controls. Average tumor weight was 90 ± 20 (mg ± SEM) for the 5 mg/kg group and 60 ± 10 mg for the 10 mg/kg group, compared to control mice given PBS (150 ± 20 mg, P < 0.05), PBL-alone (120 ± 10 mg, P < 0.005) or antibody-alone (170 ± 20 mg, P < 0.005).
We investigated whether the antibody treatment could also restrict TNBC PDTX growth. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. positive (Fig. 6D) . We examined the efficacy of MOv18-IgG1 in the fast-growing WHIM02 PDTX model that features high (100% of cells) membrane FRα expression. All WHIM02 tumors injected with PBL showed immune cell infiltration in tumor stroma irrespective of treatment ( Fig. 6E ). Average tumor weight was 350 ± 40 mg in PBL-alone group compared to 100 ± 20 mg with MOv18-IgG1 treatment (71% lower average tumor weight, P < 0.0005), suggesting significantly-reduced growth associated with antibody treatment.
Although the great proportion of infiltrating CD45 + human cells were T cells ( Supplementary Fig. 5 ), we measured a modest increase in tumor-infiltrating macrophages (3.8 ± 0.9% with MOv18-IgG1, compared to 1.2 ± 0.5% PBS, P < 0.05) and NK cells (5.7 ± 1.5% with MOv18-IgG1, compared to 1.7± 0.5% PBS, P < 0.05) (Fig. 6G ) associated with antibody treatment. This is consistent with the immune activation seen in vitro.
Our results therefore demonstrate significant tumor growth restriction associated with anti-FRα antibody in both orthotopic TNBC line and PTDX models. These effects may at least partly be attributed to a responsive, antibody-dependent, immune effector cell mechanism, a notion supported by MOv18-IgG1-mediated tumor/immune cell interactions and ADCC/ADCP functions against cancer cells. 
Discussion
Cytotoxic chemotherapy remains the only systemic treatment modality for patients with TNBC, partly because tumor-associated molecules amenable to targeted therapies including antibodies need to be identified and validated. Our genomic and immunohistochemical evaluations demonstrate that a significant population of TNBCs, including viable post-neoadjuvant chemotherapy residual disease, are likely to overexpress the tumor-associated antigen FRα, and that this antigen participates in the biological functions of breast cancer cells. We show that monoclonal antibody approaches recognizing FRα can offer treatment strategies against TNBC, such as through the design of an antibody conjugate to specifically deliver a signaling blocking agent (Fig. 4) .
Avoiding immune destruction is considered a hallmark of cancer (42) , yet recent breakthroughs demonstrate that the immune system can play important roles in controlling malignant disease, and that antibodies can provide a means by which immune cells could be directed against cancer. For example, treatment with anti-PD-1 inhibitor antibody pembrolizumab could confer clinical responses in 18.5% of patients with advanced TNBC pre-screened for expression of the ligand PD-L1 in tumors [NCT01848834] (43) .
Antibodies such as our anti-FRα clone, can also engender immune-mediated cancer cell killing via engagement of Fc receptors-expressing effector cells (monocytes, macrophages, NK cells). We exemplify these properties using patient immune effector cells in vitro and in orthotopic and patient-derived TNBC models in vivo ( Fig. 5-6 ).
Design of anti-tumor antibodies requires selection of a target, ideally one overexpressed by cancer cells and possibly associated with engendering biological advantages to cancer.
This may permit selective recognition of more aggressive cancer cells and may facilitate their destruction by targeted treatments, or engagement and activation of effector cells in the immune stroma. We provide evidence to support further evaluation of FRα as a promising target for treatment of a subset of breast cancers. We report that high FRα expression and dysregulated folate metabolic pathway may be associated with basallike/TNBC phenotype. Importantly, FRα is expressed in high-risk high-grade disease and in post-neoadjuvant chemotherapy residual tumors, themselves associated with high metastatic relapse. Targeted therapies centered on FRα may also benefit from reported low and restricted FRα expression to a small subset of non-malignant tissues (44) . We demonstrate that FRα expression confers proliferative and clonogenic advantages to tumor cells and contributes to pathway activation of Src-family non-receptor tyrosine kinases. FRα expression has been shown to associate with STAT3/JAK signaling before Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 (37) , and, here in this report, to contribute to cancer cell signaling through the Src/ERK pathway. These insights point to new opportunities for targeting FRα and for disrupting its associated signaling cascades using a specific inhibitor ( Fig. 3-4 ).
We demonstrate that FRα-expressing cells can be subjected to human volunteer and TNBC patient-derived immune cell-mediated killing with MOv18-IgG1. These effects were not seen against low FRα-expressing cells, suggesting potentially low or no on-target/offtumor toxic effects. Lowly-expressing normal tissues, mostly rely on other routes of folate uptake, namely the reduced folate carrier or proton-coupled folate transporter. The ability of this antibody to induce ADCP/ADCC against cancer cells in an antigen-dependent manner supports continued study of this and potentially other antibody strategies as passive immunotherapies for breast tumors. Our investigations of therapeutic efficacy in orthotopic xenografts showed significant reduction in tumor growth in both TNBC line and PDTX tumors. Additionally, PDTX studies revealed an increase in tumor-infiltrating macrophages and NK cells associated with anti-FRα antibody treatment. This may suggest that targeted therapy with antibodies could present an opportunity to influence the immune stroma, enhance cancer cell recognition by effector cells and ultimately activate these cells to control tumor growth (45, 46) . Our findings point to a functionally-active antibody able to prime an anti-tumor immune response that is potentially relevant and translatable to the human cancer setting.
Despite their aggressive clinical behavior, TNBCs tend to initially respond better to neoadjuvant chemotherapy compared with other breast cancer types (47) . Furthermore, chemotherapeutic agents may have immunomodulatory activity within the tumor microenvironment, supporting the presence of tumor-infiltrating lymphocytes (48) .
However, five-year survival rates remain significantly worse in TNBC than in non-TNBC patients, likely driven by chemotherapy-resistant cells, possibly residing in micrometastatic sites that subsequently lead to lethal clinical recurrence (35) . We detected FRαpositive tumors in post-neoadjuvant treated residual TNBCs. As residual TNBCs that contain low densities of tumor-infiltrating immune cells after neoadjuvant chemotherapy have a higher risk of relapse (49) , FRα-targeting antibody may present a potential strategy to retain or recruit immune effector cells in tumor stroma. TNBC is expected. The concept of using FRα-specific anti-folate drugs is evaluated in an early phase I trial of the first-in-class thymidylate synthase inhibitor, ONX-0801, in solid tumors [NCT02360345] (19) . Furthermore, with the same specificity for an epitope of FRα, the MOv18-IgE isotype is being evaluated in a first-in-class clinical trial for ovarian cancer [NCT02546921] (50) . Clinical experience with these agents points to a need for improved patient selection and for elucidating mechanisms of action. In breast cancer, FRα expression levels could be used for patient stratification. Perhaps tumor infiltration of key effector cells that may be activated against highly-aggressive or chemotherapy-resistant cancer cells, could also be employed to monitor treatment responses or to select patients more likely to benefit.
Collectively, our findings support FRα expression at the transcriptomic and protein levels, and cell surface expression in a proportion of basal-like and TNBC subtypes, including in neoadjuvant chemotherapy-resistant tumors. We report associations of higher expression with worse clinical outcomes, and evidence for functional significance in breast cancer cell biology. We demonstrate the potential tumor-restricting effects of anti-FRα MOv18-IgG1;
by potentiating immune effector cell activation and cancer cell-neutralizing functions in vitro and by restricting tumor growth in orthotopic TNBC line and PDTX models in vivo; by an ADC design approach of the anti-FRα antibody coupled with a Src-family kinase inhibitor in vitro and in vivo. Our findings point to FRα as a promising antigen for different antibody therapy approaches and may provide the basis for further translational investigations, effective patient stratification and personalized therapies, especially for patients who do not adequately benefit from currently-available treatments.
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Figure legends
